Intracellular delivery of paclitaxel using oil-free, shell cross-linked HSA - Multi-armed PEG nanocapsules

Biomaterials

Volumn 32, Issue 33, 2011, Pages 8635-8644

  Lee, Jeong Yu ^a   Bae, Ki Hyun ^a   Kim, Jee Seon ^a   Nam, Yoon Sung ^a   Park, Tae Gwan ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

Cell penetrating peptide; Drug delivery system; Human serum albumin; Nanocapsule; Paclitaxel

Indexed keywords

ANTI-CANCER AGENTS; ANTI-TUMOR ACTIVITIES; ANTICANCER DRUG; AVERAGE DIAMETER; CANCER THERAPY; CELL-PENETRATING PEPTIDE; CELLULAR UPTAKE; DELIVERY VEHICLE; DRUG ADMINISTRATION; DRUG CARRIER; DRUG DELIVERY SYSTEM; HUMAN SERUM ALBUMINS; INTRACELLULAR DELIVERY; MOUSE TUMORS; NANO SCALE; PACLITAXEL; PASSIVE TARGETING; SOLID TUMORS; SPHERICAL SHAPE; THERAPEUTIC EFFICACY;

BODY FLUIDS; CELL DEATH; DICHLOROMETHANE; DISEASES; DRUG DELIVERY; EMULSIFICATION; GLYCOLS; NANOSTRUCTURED MATERIALS; NANOTECHNOLOGY; PEPTIDES; PHASE INTERFACES; POLYETHYLENE GLYCOLS; TUMORS;

NANOCAPSULES;

AMINE; CELL PROTEIN; DICHLOROMETHANE; HPH1 PROTEIN; HUMAN SERUM ALBUMIN; MACROGOL; NANOCAPSULE; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; CROSS LINKING; DRUG DELIVERY SYSTEM; DRUG UPTAKE; EMULSION; INTRACELLULAR SPACE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICROSCOPY, CONFOCAL; NANOCAPSULES; NEOPLASMS, EXPERIMENTAL; PACLITAXEL; POLYETHYLENE GLYCOLS; SERUM ALBUMIN;

EID: 80052970758     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.07.063     Document Type: Article

References (39)

1. Adams J.D., Flora K.P., Goldspiel B.R., Wilson J.W., Arbuck S.G., Finley R. Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst Monographs 1993, 141-147.
2. Gelderblom H., Verweij J., Nooter K., Sparreboom A., Cremophor E.L. the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001, 37:1590-1598.
3. Hudis C.A. The current state of adjuvant therapy for breast cancer: focus on paclitaxel. Semin Oncol 1999, 26:1-5.
4. Weiss R.B., Donehower R.C., Wiernik P.H., Ohnuma T., Gralla R.J., Trump D.L., et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990, 8:1263-1268.
5. He X.M., Carter D.C. Atomic structure and chemistry of human serum albumin. Nature 1992, 358:209-215.
6. Green M.R., Manikhas G.M., Orlov S., Afanasyev B., Makhson A.M., Bhar P., et al. Abraxane, a novel cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006, 17:1263-1268.
7. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003, 2:347-360.
8. Nam Y.S., Kang H.S., Park J.Y., Park T.G., Han S.H., Chang I.S. New micelle-like polymer aggregates made from PEI-PLGA diblock copolymers: micellar characteristics and cellular uptake. Biomaterials 2003, 24:2053-2059.
9. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
10. Saad M., Garbuzenko O.B., Ber E., Chandna P., Khandare J.J., Pozharov V.P., et al. Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging?. J Control Release 2008, 130:107-114.
11. Lee H., Lee K., Park T.G. Hyaluronic acid-paclitaxel conjugate micelles: synthesis, characterization, and antitumor activity. Bioconjug Chem 2008, 19:1319-1325.
12. Lee S.C., Huh K.M., Lee J., Cho Y.W., Galinsky R.E., Park K. Hydrotropic polymeric micelles for enhanced paclitaxel solubility: in vitro and in vivo characterization. Biomacromolecules 2007, 8:202-208.
13. Lee K., Bae K.H., Lee Y., Lee S.H., Ahn C.H., Park T.G. Pluronic/polyethylenimine shell crosslinked nanocapsules with embedded magnetite nanocrystals for magnetically triggered delivery of siRNA. Macromol Biosci 2010, 10:239-245.
14. Bae K.H., Lee Y., Park T.G. Oil-encapsulating PEO-PPO-PEO/PEG shell cross-linked nanocapsules for target-specific delivery of paclitaxel. Biomacromolecules 2007, 8:650-656.
15. Bae K.H., Ha Y.J., Kim C., Lee K.R., Park T.G. Pluronic/chitosan shell cross-linked nanocapsules encapsulating magnetic nanoparticles. J Biomater Sci Polym Ed 2008, 19:1571-1583.
16. Choi S.H., Lee S.H., Park T.G. Temperature-sensitive pluronic/poly(ethylenimine) nanocapsules for thermally triggered disruption of intracellular endosomal compartment. Biomacromolecules 2006, 7:1864-1870.
17. Choi J.M., Ahn M.H., Chae W.J., Jung Y.G., Park J.C., Song H.M., et al. Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation. Nat Med 2006, 12:574-579.
18. Choi S.W., Lee S.H., Mok H., Park T.G. Multifunctional siRNA delivery system: polyelectrolyte complex micelles of six-arm PEG conjugate of siRNA and cell penetrating peptide with crosslinked fusogenic peptide. Biotechnol Prog 2010, 26:57-63.
19. Nori A., Kopecek J. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv Drug Deliv Rev 2005, 57:609-636.
20. Lee M., Cho Y.W., Park J.H., Chung H.S., Jeong S.Y., Choi K.W., et al. Size control of self-assembled nanoparticles by an emulsion/solvent evaporation method. Colloid Polym Sci 2006, 284:506-512.
21. Lee H., Kim I.K., Park T.G. Intracellular trafficking and unpacking of siRNA/quantum dot-PEI complexes modified with and without cell penetrating peptide: confocal and flow cytometric FRET analysis. Bioconjug Chem 2010, 21:289-295.
22. Kratz F., Fichtner I., Beyer U., Schumacher P., Roth T., Fiebig H.H., et al. Antitumour activity of acid labile transferrin and albumin doxorubicin conjugates in in vitro and in vivo human tumour xenograft models. Eur J Cancer 1997, 33:784.
23. Dreis S., Rothweiler F., Michaelis M., Cinatl J., Kreuter J., Langer K. Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int J Pharm 2007, 341:207-214.
24. Carter D.C., Ho J.X. Structure of serum albumin. Adv Protein Chem 1994, 45:153-203.
25. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008, 132:171-183.
26. Gong J., Huo M., Zhou J., Zhang Y., Peng X., Yu D., et al. Synthesis, characterization, drug-loading capacity and safety of novel octyl modified serum albumin micelles. Int J Pharm 2009, 376:161-168.
27. Terada H., Hiramatsu K., Aoki K. Heat denaturation of serum albumin monitored by 1-anilino-naphthalene-8-sulfonate. Biochim Biophys Acta 1980, 622:161-170.
28. Tuma P.L., Hubbard A.L. Transcytosis: crossing cellular barriers. Physiol Rev 2003, 83:871-932.
29. Johnsen H., Schmid R.B. Preparation of polyurethane nanocapsules by miniemulsion polyaddition. J Microencapsul 2007, 24:731-742.
30. Bae K.H., Moon C.W., Lee Y., Park T.G. Intracellular delivery of heparin complexed with chitosan-g-poly(ethylene glycol) for inducing apoptosis. Pharm Res 2009, 26:93-100.
31. Axel D.I., Kunert W., Goggelmann C., Oberhoff M., Herdeg C., Kuttner A., et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997, 96:636-645.
32. Kim B.S., Smith R.C., Poon Z., Hammond P.T. MAD (multiagent delivery) nanolayer: delivering multiple therapeutics from hierarchically assembled surface coatings. Langmuir 2009, 25:14086-14092.
33. Thiel C., Nix M. Efficient transfection of primary cells relevant for cardiovascular research by nucleofection. Methods Mol Med 2006, 129:255-266.
34. Langer K., Balthasar S., Vogel V., Dinauer N., von Briesen H., Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm 2003, 257:169-180.
35. Kim H., Robinson S.B., Csaky K.G. Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina. Pharm Res 2009, 26:329-337.
36. Stayton P.S., Hoffman A.S., Murthy N., Lackey C., Cheung C., Tan P., et al. Molecular engineering of proteins and polymers for targeting and intracellular delivery of therapeutics. J Control Release 2000, 65:203-220.
37. Mo Y., Lim L.Y. Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer activity by surface conjugation with wheat germ agglutinin. J Control Release 2005, 108:244-262.
38. Maeda H., Bharate G.Y., Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 2009, 71:409-419.
39. Kim K., Kim J.H., Park H., Kim Y.-S., Park K., Nam H., et al. Tumor-homing multifunctional nanoparticles for cancer theragnosis: simultaneous diagnosis, drug delivery, and therapeutic monitoring. J Control Release 2010, 146:219-227.